| NCCN guidelines® insights: prostate cancer, version 1.2023: featured updates to the NCCN guidelines EM Schaeffer, S Srinivas, N Adra, Y An, D Barocas, R Bitting, A Bryce, ... Journal of the National Comprehensive Cancer Network 20 (12), 1288-1298, 2022 | 201 | 2022 |
| CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD … ES Antonarakis, P Isaacsson Velho, W Fu, H Wang, N Agarwal, ... JCO precision oncology 4, 370-381, 2020 | 188 | 2020 |
| Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206 N Adra, LH Einhorn, SK Althouse, NR Ammakkanavar, D Musapatika, ... Annals of Oncology 29 (1), 209-214, 2018 | 165 | 2018 |
| High-dose chemotherapy and autologous peripheral-blood stem-cell transplantation for relapsed metastatic germ cell tumors: the Indiana University experience N Adra, R Abonour, SK Althouse, C Albany, NH Hanna, LH Einhorn Journal of Clinical Oncology 35 (10), 1096-1102, 2017 | 158 | 2017 |
| Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology EM Schaeffer, S Srinivas, N Adra, Y An, D Barocas, R Bitting, A Bryce, ... Journal of the National Comprehensive Cancer Network 21 (10), 1067-1096, 2023 | 108 | 2023 |
| LBA67 Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER … M Allaf, SE Kim, LC Harshman, DF McDermott, VA Master, S Signoretti, ... Annals of Oncology 33, S1432-S1433, 2022 | 87 | 2022 |
| Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors C Albany, N Adra, AC Snavely, C Cary, TA Masterson, RS Foster, ... Annals of Oncology 29 (2), 341-346, 2018 | 81 | 2018 |
| Testicular cancer update N Adra, LH Einhorn | 73 | 2017 |
| [68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: A VISION substudy. P Kuo, J Hesterman, K Rahbar, AT Kendi, XX Wei, B Fang, N Adra, ... Journal of Clinical Oncology 40 (16_suppl), 5002-5002, 2022 | 61 | 2022 |
| Prognostic factors in patients with poor-risk germ-cell tumors: a retrospective analysis of the Indiana University experience from 1990 to 2014 N Adra, SK Althouse, H Liu, MJ Brames, NH Hanna, LH Einhorn, ... Annals of Oncology 27 (5), 875-879, 2016 | 51 | 2016 |
| Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer F Taza, AE Holler, W Fu, H Wang, N Adra, C Albany, R Ashkar, HH Cheng, ... JCO Precision Oncology 5, 1200-1220, 2021 | 50 | 2021 |
| Integrated expression of circulating miR375 and miR371 to identify teratoma and active germ cell malignancy components in malignant germ cell tumors L Nappi, M Thi, N Adra, RJ Hamilton, R Leao, JM Lavoie, M Soleimani, ... European Urology 79 (1), 16-19, 2021 | 49 | 2021 |
| 609O Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant … B Tran, L Horvath, T Dorff, M Rettig, MP Lolkema, JP Machiels, S Rottey, ... Annals of Oncology 31, S507, 2020 | 47 | 2020 |
| Surgery in early metastatic seminoma: a phase II trial of retroperitoneal lymph node dissection for testicular seminoma with limited retroperitoneal lymphadenopathy S Daneshmand, C Cary, T Masterson, L Einhorn, N Adra, SA Boorjian, ... Journal of Clinical Oncology 41 (16), 3009-3018, 2023 | 45 | 2023 |
| Tumor frameshift mutation proportion predicts response to immunotherapy in mismatch repair‐deficient prostate cancer LA Sena, J Fountain, P Isaacsson Velho, SJ Lim, H Wang, E Nizialek, ... The Oncologist 26 (2), e270-e278, 2021 | 45 | 2021 |
| Phase Ib/II neoadjuvant (N-) pembrolizumab (P) and chemotherapy for locally advanced urothelial cancer (laUC): Final results from the cisplatin (C)-eligible cohort of HCRN GU14 … CJ Hoimes, N Adra, MT Fleming, HZ Kaimakliotis, J Picus, ZL Smith, ... Journal of Clinical Oncology 38 (15_suppl), 5047-5047, 2020 | 43 | 2020 |
| Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS) P Grivas, Y Loriot, R Morales-Barrera, MY Teo, Y Zakharia, S Feyerabend, ... BMC cancer 21 (1), 593, 2021 | 42 | 2021 |
| Phase II neoadjuvant (N-) gemcitabine (G) and pembrolizumab (P) for locally advanced urothelial cancer (laUC): Interim results from the cisplatin (C)-ineligible cohort of GU14-188. HZ Kaimakliotis, N Adra, WK Kelly, EJ Trabulsi, RC Lauer, J Picus, ... Journal of Clinical Oncology 38 (15_suppl), 5019-5019, 2020 | 39 | 2020 |
| Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic … B Tran, L Horvath, M Rettig, K Fizazi, MP Lolkema, TB Dorff, R Greil, ... Journal of Clinical Oncology 38 (15_suppl), TPS5590-TPS5590, 2020 | 31 | 2020 |
| A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer C Albany, Z Fazal, R Singh, E Bikorimana, N Adra, NH Hanna, ... Cancer medicine 10 (1), 156-163, 2021 | 28 | 2021 |
